Annual report pursuant to Section 13 and 15(d)

Stockholders' Equity (Narrative) (Details)

v3.23.3
Stockholders' Equity (Narrative) (Details)
 12 Months Ended
Oct. 07, 2022
May 09, 2022
USD ($)
$ / shares
shares
Oct. 31, 2021
$ / shares
Feb. 23, 2017
USD ($)
shares
Jun. 30, 2023
USD ($)
$ / shares
shares
Jun. 30, 2022
$ / shares
shares
Aug. 04, 2023
$ / shares
shares
Aug. 03, 2023
$ / shares
Dec. 06, 2022
shares
Jul. 19, 2022
shares
Nov. 01, 2021
$ / shares
shares
Stockholders' Equity [Line Items]                      
Preferred Stock, shares authorized         1,000,000 1,000,000          
Preferred stock, shares outstanding (in shares)         0 1,000          
Preferred stock, par value (in dollars per share) | $ / shares         $ 0.001 $ 0.001          
Common stock, shares authorized (in shares)         275,000,000 275,000,000          
Exercise of stock options (in shares)         0 3,380          
Stockholders' Equity Note, Stock Split, Conversion Ratio 0.04                    
Weighted average risk-free interest rate                      
Stockholders' Equity [Line Items]                      
Fair value of the Warrant assumptions         0.23            
Dividend yield                      
Stockholders' Equity [Line Items]                      
Fair value of the Warrant assumptions         0            
Volatility                      
Stockholders' Equity [Line Items]                      
Fair value of the Warrant assumptions         136.9            
Expected term (in years)                      
Stockholders' Equity [Line Items]                      
Fair value of the Warrant assumptions         4.95            
College Station Investors LLC And Bryan Capital [Member]                      
Stockholders' Equity [Line Items]                      
Warrants, exercise price per share | $ / shares                     $ 33.25
Warrants to purchase shares of Common Stock                     51,583
H.C. Wainwright & Co., LLC [Member]                      
Stockholders' Equity [Line Items]                      
Proceeds from exercise of warrants | $         $ 2,207,000            
Warrants to purchase shares of Common Stock                 201,923    
Pre Funded Warrants [Member] | H.C. Wainwright & Co., LLC [Member]                      
Stockholders' Equity [Line Items]                      
Warrants, exercise price per share | $ / shares         $ 0.001            
Series A warrants                      
Stockholders' Equity [Line Items]                      
Warrants, exercise price per share | $ / shares             $ 0.50 $ 1.04      
Warrants to purchase shares of Common Stock             3,475,916        
Series A warrants | H.C. Wainwright & Co., LLC [Member]                      
Stockholders' Equity [Line Items]                      
Warrants, exercise price per share | $ / shares         $ 1.04            
Term of the warrants         5 years            
Exercise of warrants (in shares)         341,300            
Warrants to purchase shares of Common Stock                 504,807    
Series B warrants                      
Stockholders' Equity [Line Items]                      
Warrants, exercise price per share | $ / shares             $ 0.50 $ 1.04      
Warrants to purchase shares of Common Stock             2,058,000        
Series B warrants | H.C. Wainwright & Co., LLC [Member]                      
Stockholders' Equity [Line Items]                      
Warrants, exercise price per share | $ / shares         $ 1.04            
Term of the warrants         2 years            
Exercise of warrants (in shares)         1,781,216            
Warrants to purchase shares of Common Stock                 504,807    
Representative Warrants [Member] | H.C. Wainwright & Co., LLC [Member]                      
Stockholders' Equity [Line Items]                      
Warrants, exercise price per share | $ / shares         $ 1.30            
Term of the warrants         5 years            
iBio CMO Preferred Tracking Stock [Member]                      
Stockholders' Equity [Line Items]                      
Preferred Stock, Dividend Rate, Percentage       2.00%              
Preferred Stock, Dividends Per Share, Declared | $ / shares     $ 0                
Preferred stock, shares outstanding (in shares)                     0
Series 2022 Convertible Preferred Stock [Member]                      
Stockholders' Equity [Line Items]                      
Proceeds from sale of shares, net of issuance cost | $   $ 270                  
Shares issued upon conversion                   40  
Preferred stock, par value (in dollars per share) | $ / shares   $ 0.001                  
Shares issued   1,000                  
Stockholders' Equity Note, Stock Split, Conversion Ratio   1                  
Restricted Stock Units [Member]                      
Stockholders' Equity [Line Items]                      
Shares vested         217,553 8,854          
Omnibus Incentive (the 2020) Plan [Member]                      
Stockholders' Equity [Line Items]                      
Shares available for grant under the plan         1,280,000            
Exchange Agreement [Member] | iBio CMO Preferred Tracking Stock [Member] | Bioprocessing (iBio CDMO) [Member]                      
Stockholders' Equity [Line Items]                      
Stock Issued During Period, Shares, Acquisitions       1              
Number of LLC interest units exchanged for each share of preferred tracking stock       29,990,000              
Proceeds from sale of shares, net of issuance cost | $       $ 13,000,000              
Exchange Agreement [Member] | iBio CMO Preferred Tracking Stock [Member] | After Preferred Tracking Stock Exchanged for Units of Limited Liability Company Interests [Member] | Bioprocessing (iBio CDMO) [Member]                      
Stockholders' Equity [Line Items]                      
Noncontrolling Interest, Ownership Percentage by Parent       99.99%              
Exchange Agreement [Member] | iBio CMO Preferred Tracking Stock [Member] | Eastern Affiliate [Member] | After Preferred Tracking Stock Exchanged for Units of Limited Liability Company Interests [Member] | Bioprocessing (iBio CDMO) [Member]                      
Stockholders' Equity [Line Items]                      
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners       0.01%